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Abstract 
Recent insights in RA necessitated updating the EULAR RA management recommendations. 
A large international Task Force based decisions on evidence from 3 systematic literature 
reviews, developing 4 overarching principles and 12 recommendations (versus 3 and 14, 
respectively, in 2013). The recommendations address conventional synthetic (cs) DMARDs 
(methotrexate [MTX], leflunomide, sulfasalazine); glucocorticoids (GC); biological (b) 
DMARDs (TNF-inhibitors [adalimumab, certolizumab pegol, etanercept, golimumab, 
infliximab], abatacept, rituximab, tocilizumab, clazakizumab, sarilumab and sirukumab and 
biosimilar (bs) DMARDs; and targeted synthetic (ts) DMARDs (Janus kinase [Jak] inhibitors 
tofacitinib, baricitinib). Monotherapy, combination therapy, treatment strategies (treat-to-
target) and the targets of sustained clinical remission (as defined by ACR-EULAR Boolean or 
index criteria) or low disease activity are discussed. Cost aspects were taken into 
consideration. 
  
As first strategy, the Task Force recommends MTX (rapid escalation to 25mg/week) plus 
short-term GC, aiming at >50% improvement within 3 and target attainment within 6 
months. If this fails stratification is recommended. Without unfavorable prognostic markers, 
switching to  ? or adding  ? another conventional synthetic (cs) DMARDs (plus short-term GC) 
is suggested. In the presence of unfavorable prognostic markers (autoantibodies, high 
disease activity, early erosions, failure of 2 csDMARDs), any bDMARD (current practice) or 
Jak inhibitor should be added to the csDMARD. If this fails, any other bDMARD or targeted 
synthetic (ts) DMARD is recommended. If a patient is in sustained remission, bDMARDs can 
be tapered. 
 
For each recommendation, levels of evidence and Task Force agreement are provided, both 
mostly very high. These recommendations intend informing rheumatologists, patients, 
national rheumatology societies, hospital officials, social security agencies and regulators 
  
ĂďŽƵƚh>Z ?Ɛŵost recent consensus on the management of RA, aimed at attaining best 
outcomes with current therapies. 
  
  
The management of rheumatoid arthritis (RA) has changed dramatically over the past thirty 
years. Few therapeutic agents existed then, which were either minimally or not efficacious, 
because of toxicity and the fact that optimal dosing and onset of action had not yet been 
elucidated for some agents.1-4 Available therapies were started late rather than early in the 
course of the disease.5;6 Early arthritis clinics were emerging,7-9 and their successes fueled 
reappraisal of the classification criteria then available that focused primarily upon long-
standing disease.10 A therapeutic target had not yet been defined, because relief of 
symptoms appeared to be the most important goal  and the concept of aiming at disease 
states like remission or low disease activity was at best aspirational.11  
To date, we have available numerous efficacious agents. Among the conventional synthetic 
(cs) disease modifying antirheumatic drugs (DMARDs)12 we adopted MTX, upon its optimal 
use, as the anchor drug;4 in addition, a number of biological (b) DMARDs have been 
approved, more recently followed  (in many countries) by approval of the first targeted 
synthetic (ts) DMARD, with more in development.13 Today, new classification criteria for RA 
promote the study of patients earlier in their disease course than before14 and 
recommendations have been developed to treat RA patients via strategic algorithms 
targeting an optimal outcome, irrespective of the types of available therapies.15-17  
A limited number of measures to assess response in clinical trials and follow disease activity 
in clinical practice are widely used18-21 and the American College of Rheumatology (ACR) and 
the European League Against Rheumatism (EULAR) have jointly developed new definitions 
for remission which provide an optimal clinical outcome and can be achieved in a significant 
proportion of patients in trials and practice.22 Attaining remission according to these 
criteria, index-based or Boolean, will prevent joint destruction or at least progression of 
  
joint damage irrespective of residual subclinical changes,23;24 optimize physical function, 
improve quality of life and work capacity,25;26 and reduce comorbidity risks.27;28    
With this recent evolution of evidence supporting stringent disease control to improve 
outcomes, interest in purely symptomatic drugs has significantly decreased today and 
disease modification has become the pivotal attribute of all modern drugs and treatment 
strategies. Nevertheless, symptomatic agents as well as physical measures, psychological 
support and surgery may and do have a place in the overall management of RA. However, 
disease modification is the mainstay of RA treatment and constitutes an amalgam of 
characteristics: relief of signs and symptoms; normalization  ? or at least important 
improvement  ? of impairment in physical function, quality of life and social and work 
capacity; and  ? as the foremost distinguishing characteristic of DMARDs compared to 
symptomatic agents  ? inhibition of structural damage to cartilage and bone. Therefore, 
showing inhibition of damage progression by radiography is still a pivotal outcome for the 
classification of a drug as a DMARD, since radiographs can depict bony and cartilage damage 
and have proven sensitivity to change even over short-term intervals and at very low levels 
of overall progression in a population.29;30 Rapid attainment of the targeted endpoint is now 
critical, and to achieve the treatment goal of remission or at least low disease activity within 
the time frame of 6 months, at least 50% clinical improvement within 3 months is 
desirable.31 
With rising standards of care and outcomes, RA management has become increasingly 
complex over the last decade. Despite the availability of many efficacious agents, treatment 
strategies that have been developed, and outcomes assessments that allow effective follow-
up, the high costs of novel therapies have limited the widespread use of these therapeutic 
  
options, creating a significant extent of inequity. Therefore, management recommendations 
on the approach to treating patients with RA have become increasingly useful in providing 
physicians, patients, payers, regulators and other health care suppliers with evidence-based 
guidance supported by the views of experts involved in many of these novel developments. 
Indeed, EULAR has recently updated the standardized operating procedures on the 
development of recommendations which include cost aspects in addition to accounting for 
the assessment of evidence and expert opinion.32  
EULAR developed a first set of recommendations for the management of RA with DMARDs 
in 2010 and updated them in 2013. They were originally based on the evidence provided by 
five (2010) and three (2013)33-35 systematic literature reviews (SLRs). The EULAR 
recommendations have been widely used. They have been referred to by national 
rheumatology societies and regional leagues to inform the development of their own 
recommendations (such as Canadian, French, German, Mexican, APLAR, PANLAR), as well as 
by regulatory authorities.36-42  
Consistent with our approach to providing recommendations based on the latest evidence, 
we have continued to evaluate the literature on clinical trials of new agents, new 
information on established drugs, new strategic studies, new perceptions on outcomes 
assessments and new insights related to the research agenda16 over the last three years. An 
abundance of new information motivated us to now further update the EULAR 
recommendations for the management of RA with DMARDs.  
 
Methods 
  
After approval by the EULAR Executive Committee, the Convenor (JS) and methodologist 
(RL) invited a Steering Committee and a Task Force to work on this update of the EULAR 
recommendations for the management of RA. The 2010 recommendations and their 2013 
update adhered to the original EULAR standardized operating procedures for the 
development of recommendations;43 the 2016 update followed the recently amended 
version of these standards,32 which also suggest adherence to the Appraisal of Guidelines 
for Research & Evaluation (AGREE) recommendations in its updated version (AGREE II).44  
 
Steering Committee 
The Steering Committee included 7 rheumatologists, 1 patient representative and 3 fellows. 
This group initially developed the research questions for the 3 SLRs (SLRs). These SLRs 
focused on (i) efficacy of sDMARDs (as monotherapy or combination therapy, including both 
conventional synthetic [cs] DMARDs and targeted synthetic [ts] DMARDs), and 
glucocorticoids; (ii) efficacy of bDMARDs (as monotherapy or combined with csDMARDs); 
and (iii) safety aspects of sDMARDs and biological [b] DMARDs. To this end, the original SLRs 
obtained in 201333-35 served as a starting point and an update on the literature published 
between 2013 and 2016 was performed. New information on treatment strategies was also 
evaluated in the present SLRs. Formal economic analyses were not performed, but cost 
aspects were considered throughout the process in line with the current state of the art of 
developing recommendations,45;46 h>Z ?ƐŽǁŶƉƌĞǀŝŽƵƐ^>ZŽŶĐŽƐƚĂƐƉĞĐƚƐŝŶthe context 
of DMARD therapy47 and the advent of biosimilars.48 The three rheumatology fellows (KC, 
JN, SR) performed the SLRs (and checked each other ?s work) exploiting existing publication 
databases on randomized controlled trials for efficacy and registry data for safety, and also 
  
evaluating recent EULAR and ACR congress abstracts. Summary-of-Findings (SOF) tables 
were generated and levels of evidence (LoE) were determined using the standards of the 
Oxford Centre for Evidence Based Medicine.49 The three SLRs informing the Task Force and a 
detailed description of their methods are published separately.50-52 
 
The SoFs of the SLRs were presented to the Steering Committee that formulated a proposal 
for an update of the recommendations based on this information. The SLR data and the 
proposals of the Steering Committee were subsequently presented to the whole Task Force 
for further discussions and ultimately development of the updated recommendations. 
 
 
Task Force 
The Task Force consisted of 50 individuals, including the Steering Committee members. 
Among the Task Force members were 3 patients, 2 health professionals and 2 delegates of 
ƚŚĞh>ZǇŽƵŶŐƌŚĞƵŵĂƚŽůŽŐŝƐƚƐ ?ŶĞƚǁŽƌŬDhEd ?The rheumatologists were all 
experienced in the treatment of RA and most had frequently participated in clinical trials; 
moreover, several of them had experience in patient registries of their countries or in 
various aspects of outcomes research. The patients and health professionals all had 
experience in consensus finding activities, as well as most of the rheumatologists. Since we 
also wished the Task Force ?ƐǁŽƌŬ to be informed by rheumatologists from other regions of 
the world, aside from a broad representation from 14 European countries, 2 colleagues 
from Asia, 1 from Australia, 2 from Latin America and 2 from North America were invited to 
participate. Several of them had actively participated in developing documents of their 
  
regional leagues and/or national societies. All Task Force members declared their potential 
conflicts of interest before the start of the process.   
The Task Force agreed upon a few principal considerations upfront. Firstly, all 
recommendations needed to be discussed in the context of new evidence; where no new 
evidence was available, the former evidence base was followed. Secondly, any of the 
previous recommendations (4 overarching principles and 14 recommendations) could be 
maintained as they had been presented in the 2013 version, amended, shifted in sequence 
or deleted. Thirdly, drugs that were not (yet) approved in Europe but used elsewhere in the 
world, or drugs that had not yet undergone regulatory assessment but for which evidence 
from clinical trials was available, could be considered in recommendations to allow for some 
anticipation of a potential uptake in clinical practice, with all respective caveats. Finally, 
there was agreement that all recommendations of 2013, which were either further 
supported by new evidence or lacked novel information, should be incorporated as 
previously worded, unless certain components were now considered inappropriate.     
ĨƚĞƌƚŚĞƉƌĞƐĞŶƚĂƚŝŽŶŽĨƚŚĞ^>ZƌĞƐƵůƚƐĂŶĚƚŚĞ^ƚĞĞƌŝŶŐŽŵŵŝƚƚĞĞ ?ƐƉƌŽƉŽƐĂůƐĨŽƌƚŚĞ
amendment of the recommendations, the Task Force was split into 4 breakout groups. One 
group reviewed bDMARDs, the second group csDMARDs, the third tsDMARDs, and the 
fourth glucocorticoids; all groups proposed draft language for respective recommendations 
to the whole Task Force. Safety aspects were addressed in each of these breakout groups.  
 
Consensus Finding 
  
Representatives of each breakout group reported the results of the respective deliberations 
and presented proposals for the wording of individual recommendations to the whole Task 
Force. Thereafter the voting process took place.   
For an overarching principle or recommendation to be accepted for the final document 
without further change, a majority of 75% of the votes was required in the first ballot. If this 
result was not achieved, the respective text was amended and subjected to a second ballot, 
for which a 67% majority was required. If this ballot was not successful, further textual 
changes were proposed until a A?50% majority was attained. The recommendations are 
presented as finally voted upon. The results of the respective last ballot are presented as 
percentage of voting members. Notes captured the contents of the discussions and the 
reasoning behind each decision to be presented in the comments accompanying the 
individual items. For various reasons, not every Task Force member was present in the room 
throughout the whole meeting and, therefore, there were slight variations in the numbers 
of votes. However, at every point in time more than 90% of the members participated in the 
ballots.  
After the face-to-face meeting, the recommendations, as agreed by the Task Force, were 
subjected to an anonymous vote (by e-mail) on the levels of agreement (LoA).  Each 
recommendation received an adjudication on a scale of 0-10, 0 meaning no agreement 
whatsoever and 10 absolute agreement. During this process, several weeks after the 
meeting, one individual withdrew from the Task Force, because the inclusion of csDMARD 
combination therapy in the recommendations had not found a majority during the 
preceding voting process. This colleague had been present and voted throughout the face-
to-face meeting and the respective votes regarding all recommendations are accounted for 
  
accordingly, but ultimately the person declined authorship and no vote was cast on the level 
of agreement.  
The draft of the manuscript was sent to all Task Force members for their comments. After 
incorporation of these comments it was submitted to the EULAR Executive Committee for 
review and approval; at this time it was again sent to the Task Force members. Final remarks 
were obtained from members of the Task Force and the Executive Committee and 
addressed in the manuscript which was then submitted with approval by the EULAR 
Executive Committee. 
 
 
 
Results 
General aspects 
As before, the 2016 update of the EULAR RA management recommendations reflects the 
balance of clinical, functional and structural efficacy, safety, costs and patientƐ ?ƉĞƌĐĞƉƚŝŽŶƐ 
as perceived by the Task Force. Aspect of drug-toxicity were considered in the overall 
wording of the recommendations, but data are presented only in the Safety SLR because  it 
is assumed that prescribers are aware of the safety information provided in the 
ŵĂŶƵĨĂĐƚƵƌĞƌƐ ?package inserts of the various agents. Also, EULAR has developed a series of 
documents dealing with safety aspects of RA drugs,53-58 and various other publications have 
addressed these aspects.59-62 In particular, as also suggested by the safety SLR,50 the major 
risk of bDMARDs (and also tsDMARDs) is related to infections, and recommendations for 
  
vaccination56 as well as a score allowing to calculate the risk of infection in patients exposed 
to bDMARDs have been recently developed.63;64 For all medications discussed in this paper, 
the summary of product characteristics (SPC) document provides valuable information on 
risks, side effects, and need for monitoring. The recommendations given here should in no 
way be construed so as to detract from that information. In any case, when toxicity 
constitutes a major issue, a specific warning is provided within the respective 
recommendation or the accompanying comments. Of note, the 3 SLRs as well as the text 
accompanying each item should be regarded as part and parcel of the recommendation. The 
individual bullet points represent abbreviated conclusions from the discussions and, as such, 
do not capture all aspects related to a particular theme; rather, such aspects are elucidated 
in more detail in the respective explanatory part of the Results section.  
When classifying DMARDs, the Task Force adhered to the previously used nomenclature12;16 
as shown in Table 1. This Table also provides a glossary for terms employed in the 
recommendations. The Task Force did not distinguish between early and established RA 
regarding the recommendation of the types of drugs, but rather discerned phases of the 
treatment process by differentiating between patients who are naïve to any DMARD 
therapy, patients who had an insufficient response (IR) to initial course(s) of csDMARDs and 
those who had an IR to bDMARDs. There is currently no evidence for differential responses 
solely based on disease duration, when leaving differences in baseline damage due to 
delayed treatment initiation aside. Indeed, trials on MTX-naïve RA patients used different 
disease durations for inclusion, which ranged from a few months to several years, without 
appreciable differences in outcomes upon indirect comparison.65-68 However, the Task Force 
distinguished between early and established RA in terms of the targeted outcome (see 
recommendation 2). The Task Force also took prognostic factors (Table 1) into account, 
  
which have similar predictive power irrespective of disease duration.69 Of note, 
recommendations for the management of early arthritis, including undifferentiated arthritis, 
have been recently updated.70 The present recommendations address the management of 
patients with RA from the time of its diagnosis and not pre-RA or undifferentiated arthritis.  
 
Overarching principles 
As in previous versions, the Task Force endorsed the presentation of general principles for 
the treatment of patients with RA as overarching (Table 2). Their nature is so generic that 
there was no requirement to base them on specific searches or levels of evidence, but at the 
same time the group believed it is crucial to communicate them as a foundation on which 
the actual recommendations were based. However, while all three former overarching 
principles were maintained as formulated in 2010, the Task Force added a 4th one as 
overarching principle B. 
A. Treatment of RA patients should aim at the best care and must be based on a shared 
decision between the patient and the rheumatologist. This principle remained 
unchanged both in its textual details and in its place as item A, a prominent position 
within the recommendations. Shared decision-making between patient and 
rheumatologist involves all aspects of the disease: information on the disease and its 
risks, the modalities of disease assessment, decisions on the therapeutic target and 
the potential means to reach the target, the development of a management plan 
and discussions on the benefits and risks of individual therapies. These aspects have 
also been detailed in recommendations on standards of care.71 EĂƚƵƌĂůůǇ ? “ďĞƐƚĐĂƌĞ ?
refers to the recommendations presented here and inherently  “ƐŚĂƌĞĚĚĞĐŝƐŝŽŶ ?
  
relates to all individual recommendations. To this end also quality indicators have 
been developed more recently.72  
 
B. Treatment decisions are based on disease activity and other patient factors, such as 
progression of structural damage, comorbidities and safety issues. This is a new 
principle. It derives from previous recommendation 14, the last item of the 2013 
version, which was deemed by the current Task Force to represent such a central 
and self-evident rule to any therapeutic approach that it should constitute an 
overarching principle rather than a recommendation. Indeed, in line with these 
considerations, the level of evidence of this recommendation had been rather low in 
2013. Withdrawing this item from the recommendations elicited some discussions. 
Especially the patients brought forward that ending the list of recommendations 
with an item on patient-related factors would convey prominence to patient 
preferences and patient aspects in the management of RA. However, the reasoning 
that this item would even benefit more from being a general principle than a 
recommendation, which was unlikely to ever be studied in all its subtleties, prevailed 
to an extent that principle B was unanimously accepted (Table 2). 
 
C. Rheumatologists are the specialists who should primarily care for RA patients. 
Originally presented as item B, the wording of this principle was not changed. Of 
interest, in 2010 this was even presented as overarching principle A. However, over 
the last years it was recognized, that shared decision-making and considerations of 
patient factors should receive the most prominent recognition. Whether positioned 
as A, B or C, this item addresses the importance of specialty care for a complex 
  
disease like RA. There is compelling evidence that being cared for by a 
rheumatologist is advantageous for the patients in terms of early initiation of 
therapy, prevention of damage and reduction in surgical procedures.73-77 Moreover, 
rheumatologists have the most profound experience regarding the use of csDMARDs 
and bDMARDs. This includes the adverse event profiles of these drugs, as well as 
awareness of and experience with comorbidities in RA. Therefore, rheumatologists 
can ƉƌŽǀŝĚĞƚŚĞ “ďĞƐƚĐĂƌĞ ?in accordance with item A, in the sense of a holistic 
approach. The reasoning behind ƚŚĞƚĞƌŵ “ƉƌŝŵĂƌŝůǇ ?ŚĂƐďĞĞŶĚŝƐĐƵƐƐĞĚamply in 
previous versions of the recommendations and relates to considerations of 
multidisciplinary care, including specialty nurses, and to the fact that in certain areas 
of the world Rheumatology training is not sufficiently provided and other experts 
may have experience in the management of RA. Moreover, some comorbidities, such 
as chronic hepatitis or interstitial lung disease, may require consultation of, and 
treatment by, other specialists. 
 
D. RA incurs high individual, medical and societal costs, all of which should be 
considered in its management by the treating rheumatologist. Again, this principle is 
worded exactly as last time, except that it was item C, but also last.16 It is meant to 
remind all stakeholders that effective RA therapy  ? in spite of its direct costs  ? will 
reduce the economic burden on the individual patients, their families and society, 
which not only includes direct medical costs, but also indirect costs such as work 
disability and premature retirement. In this context it must be borne in mind that 
direct medical costs accrue beyond those attributed to directly treating the overt 
manifestations of RA and include costs ensuing from comorbidities related to the 
  
inflammatory process. This point, however, is also meant to echo that cost-effective 
treatment approaches must be preferred as long as safety and outcomes are similar 
compared with more costly ones and in line with the therapeutic paradigms.46 In 
some countries, the high cost of treatment is an important factor limiting the 
availability of modern therapies (inequity) , and this factor has to be considered 
when choosing a treatment strategy.78 In this respect, the advent of biosimilars 
provides potential for reduction of pressure on health care budgets.48 At this point it 
also must be considered that many patients still do not attain the therapeutic 
targets, despite all of our modern therapies and therapeutic strategies. Furthermore, 
any of the bDMARDs, if applied after at least one csDMARD and a bDMARD has 
failed, leads to only about 10% good treatment responses in terms of ACR70 rates.79 
These aspects impose the need to continue the search for new therapies or 
strategies. 
 
Recommendations   
General aspects 
dŚĞdĂƐŬ&ŽƌĐĞ ?s deliberative process resulted in 12 recommendations. The reduction by 2 
recommendations compared with the past EULAR document may be somewhat surprising 
given the allegedly increasing intricacy of therapeutic modalities and strategies. However, 
the content of recommendation 14 was shifted into the overarching principles as discussed 
above. Moreover, item 11 of the 2013 version, which addressed the use of tofacitinib, was 
deleted as a separate item, because Janus kinase inhibitors as tsDMARDs have now entered 
into and expanded other recommendations; this will be discussed in more detail in the 
  
context of items 8, 9 and 10. Also former recommendation 6, which addressed the use of 
csDMARD combinations, was deleted by the Task Force; combination therapy with 
csDMARDs and the reasons to remove it from its previous prominence within the list of 
recommendations and the algorithm will be addressed in the discussion on 
recommendations 4 and 5. While 3 of the 2013 recommendations were deleted via either 
complete omission or incorporation into other items, former recommendation 8 which 
addressed the absence or presence of prognostic risk factors was split into new 
recommendations 7 and 8; a detailed rationale for this decision is discussed below.  
The 12 recommendations form a logical sequence. They start with the need to initiate 
effective therapy immediately after diagnosis and the requirement to set a treatment target 
and to assess the disease on the way toward that target, employing a treat-to-target 
strategy. Such strategy has been strongly embedded into the recommendations since their 
first version in 2010. With these prerequisites in mind, different drugs or combinations of 
agents are recommended in the course of the therapeutic procedures, with suggested 
sequential increments, taking prognostic factors and all approved agents into account. They 
also mention some agents of potential future interest, even though not yet approved by 
international regulatory authorities. Thus, the recommendations also include a prospective 
view on drugs that have undergone phase 3 trials and were available for evidence 
assessment; obviously their actual prescription will depend on the regulatory approval 
status in individual countries. The set of recommendations concludes with suggestions 
toward reduction of therapy and even withdrawal of some drugs when the desired target 
has been attained and is sustained.  
 
  
Individual recommendations 
1. Therapy with DMARDs should be started as soon as the diagnosis of RA is made. This 
recommendation remained unchanged compared with 2013 and is one of the 
mainstays of any treatment approach to RA. It implies (i) the necessity to establish a 
diagnosis as early as possible, as has been reflected also in the 2010 ACR-EULAR 
classification criteria;14 80;81 and (ii) the advantage of early initiation of DMARD 
ƚƌĞĂƚŵĞŶƚ ? “ĂƐƐŽŽŶĂƐƉŽƐƐŝďůĞ ? ?, which enables prevention of damage in a large 
proportion of patients.76;82-84 Because of the generic nature of this bullet point, the 
Task Force did not specify the type of DMARD here. Indeed, all DMARDs enable a 
better long-term outcome upon early, compared with delayed institution, and the 
sequence of the types of DMARD therapies is addressed in subsequent 
recommendations. The Task Force did not deal with pre-RA or undifferentiated 
arthritis and thus assumed that a diagnosis of RA had already been made. However, 
it should be borne in mind that any chronic arthritis, even if undifferentiated, 
requires appropriate treatment, including consideration of DMARD therapy, because 
it usually does not subside spontaneously,85;86 and an update of the 
recommendations for management of early arthritis has just been presented by 
EULAR.70 With a level of agreement of 9.9, this recommendation achieved the 
highest agreement of all items (Table 2). LoE 1a; LoA 9.9 
 
2. Treatment should be aimed at reaching a target of sustained remission or low 
disease activity in every patient.  This recommendation addresses two treatment 
targets: remission, especially in DMARD-naïve patients, and low disease activity, 
primarily in patients who failed previous therapies. Since clinical remission or low 
  
disease activity are mentioned as the sole therapeutic targets, any higher disease 
activity state has to be regarded as inadequate disease control, thus mandating a 
therapeutic change, obviously unless patient factors preclude this.15 Communication 
with the patient to clarify and agree on the treatment goal and the means to attain 
ƚŚŝƐŐŽĂůŝƐŽĨƵƚŵŽƐƚŝŵƉŽƌƚĂŶĐĞ ?/ƚĂůůŽǁƐĂůŝŐŶŵĞŶƚŽĨƚŚĞƉĂƚŝĞŶƚ ?ƐĂŶĚƉƌŽǀŝĚĞƌ ?Ɛ
considerations and aims and enhances adherence. In 2010, the nŽƚŝŽŶ “ĂƐƐŽŽŶĂƐ
ƉŽƐƐŝďůĞ ?ǁĂƐĂůƐŽƉĂƌƚŽĨƚŚŝƐŝƚĞŵ87 and in the current discussion it was specifically 
decided to mention that the treatment target should be rapidly attained rather than 
aiming to achieve it in a more distant future. Indeed, there is sufficient evidence that 
most patients who do not attain significant improvement within 3 months, or do not 
achieve the treatment target within 6 months, will not reach the desired state 
subsequently;31;88-90 exceptions pertain to those patients whose disease activity has 
been reduced to a level close to the treatment target.   
Regarding remission, EULAR and ACR have agreed on Boolean and index-based 
definitions, the latter based on the simplified or clinical disease activity index (SDAI, 
CDAI).22 Both correlate highly with the absence of subclinical synovitis by magnetic 
resonance imaging and sonography91;92 and absence of progression of joint 
damage.23 They can even be reliably used when drugs that interfere directly with the 
acute phase response are employed.93-96 Moreover, recent strategic clinical trials 
that compared targeting sonographic remission with targeting clinical remission or 
low disease activity resulted in the conclusions that aiming at imaging remission had 
no advantages over the clinical target, but economic disadvantages.97;98 Low disease 
activity also needs to be properly defined and measured. Measures that highly weigh 
CRP or ESR (e.g. the DAS28) may not convey sufficiently reliable results when used 
  
with agents that interfere with the acute phase response, such as anti-cytokine 
agents (especially IL-6 inhibitors) or Jak inhibitors.93;96;99  
It is important that the target-state should be sustained. dŚĞƚĞƌŵ “ƐƵƐƚĂŝŶĞĚ ?ŝƐƐƚŝůů
not defined precisely, and different studies have used different definitions, but some 
voices in the Task Force suggested at least 6 months as a minimal time frame. This 
requires follow-up and a strategy to adapt therapy intensity up- or downward, 
aspects that are dealt with in subsequent recommendations. However, treatment 
intensification must take patient factors into consideration, especially risks and 
comorbidities (overarching principle B). LoE 1a; LoA 9.6 
  
3. Monitoring should be frequent in active disease (every 1 ?3 months); if there is no 
improvement by at most 3 months after the start of treatment or the target has not 
been reached by 6 months, therapy should be adjusted. This recommendation on 
treat-to-target is unchanged in position and formulation from the 2013 version. The 
frequencies of follow-up examinations should be adjusted in accordance with the 
level of disease activity, namely more frequently, such as monthly, when patients 
have high disease activity, and less frequently, such as every 6 to 12 months when 
the treatment target has been attained and sustained. EULAR generally recommends 
the use of a composite measure of disease activity that includes joint counts and the 
ACR-EULAR definitions for remission.22;100 Improvement by 3 months refers to the 
fact that if a minimal change is not achieved, there is only a low likelihood of 
reaching the treatment target. Thus, a change to a better disease activity state 
should be seen at 3 months or a relative improvement, pertaining to at least 50% 
improvement in activity by a composite score, at that point in time, in order to have 
  
a considerable chance of reaching the target.31;89;101;102 Of note, adjustment of 
therapy includes the optimization of MTX (or other csDMARD) dose or route of 
administration,4 or intraarticular injections of glucocorticoids in the presence of one 
or few residual active joints, and refers to a change of drugs only if these measures 
have not been successful or are not appropriate. Further, in an individual patient the 
treatment target may not have been fully achieved yet at 6 months. But if disease 
activity is close to the target, one may think about  continuing the effective therapy 
for a few more weeks to make a final judgment, especially since a considerable 
proportion of patients may attain the target at a slightly later time point than at 6 
months.103;104 Consequently, the change in disease activity from baseline, and its 
slope should be considered when making treatment decisions. LoE 2b; LoA 9.5 
 
4. MTX should be part of the first treatment strategy. Compared with 2013, when this 
ŝƚĞŵƌĞĂĚ “MTX should be part of the first treatment strategy in patients with active 
Z ? ?ƚŚĞƌĞĐŽŵŵĞŶĚĂƚŝŽŶǁĂƐƐůŝŐŚƚůǇƐŚŽƌƚĞŶĞĚ ?dŚĞdĂƐŬ&ŽƌĐĞĨĞůƚƚŚĂƚpointing 
to active disease was not necessary, since the EULAR recommendations primarily 
address patients with active disease. Based on its efficacy, safety (especially in the 
presence of folic acid), the possibility to individualize dose and method of 
administration as well as relatively low costs, MTX continues to be the anchor 
 ? “ĨŝƌƐƚ ? ?ĚƌƵŐĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚZďŽƚŚĂƐŵŽŶŽƚŚĞƌĂƉǇĂƐǁĞůůĂƐŝŶĐŽŵďŝŶĂƚŝŽŶ
ǁŝƚŚŽƚŚĞƌĚƌƵŐƐ ? “ƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐǇ ?; see below). Moreover, MTX appears to 
reduce comorbidities and mortality in RA.105;106 In clinical trials of bDMARDs in early 
arthritis patients, MTX-monotherapy has been associated with 25% ACR70 response 
rates (which brings patients into the range of low disease activity) within 6 months, 
  
even though it had not been combined with de novo glucocorticoids in these trials.79 
MTX should be rapidly escalated, usually to 25-30mg/week, orally or subcutaneously 
administered, with folic acid supplementation,4 and the maximal MTX dose, if 
tolerated, should be sustained for about 8-12 weeks to judge the MTX treatment 
response. Indeed, when MTX is rapidly escalated to 25mg per week, the response 
rate may even be higher (~40% low disease activity).107 Of course, contraindications 
and the potential of early toxicity have to be taken into account; this is addressed in 
item 5. The doses mentioned here do not pertain to Asian patients. In China, it is not 
recommended to exceed 20mg/week104 and in Japan the maximum recommended 
dose for MTX is 16mg/week.108 
Of note, at this point in time the Task Force decided to delete previous 
ƌĞĐŽŵŵĞŶĚĂƚŝŽŶ ? ? “In DMARD-naïve patients, irrespective of the addition of 
glucocorticoids, csDMARD monotherapy or combination therapy of csDMARDs 
should be used ? ? ?dŚĞŝŶĐůƵƐŝŽŶŽƌĞǆĐůƵƐŝŽŶŽĨĐŽŵďŝŶĂƚŝŽŶƐŽĨĐƐDZƐ within 
the bullet points elicited long debates within the respective breakout group and the 
whole Task Force (and the withdrawal of one Task Force member).  
The first ballot of the Task Force involved a choice of the following two wordings: (a) 
 “DdyƐŚŽƵůĚďĞƉĂƌƚŽĨƚŚĞĨŝƌƐƚƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐǇ ?ĂŶĚ ?ď ?  “In DMARD-naïve 
patients, irrespective of the addition of glucocorticoids, csDMARD monotherapy or 
ĐŽŵďŝŶĂƚŝŽŶƚŚĞƌĂƉǇŽĨĐƐDZƐƐŚŽƵůĚďĞƵƐĞĚ ? ?ŝĚĞŶƚŝĐĂůǁŝƚŚƚŚĞƌĞƐƉĞĐƚŝǀĞ
2013 recommendation), with 23 votes favoring (a), 22 votes favoring (b) and 1 
abstention. Therefore further discussions took place. Advocates in favor of including 
combination therapy referred to publications suggesting its superior efficacy 
compared with csDMARD monotherapy and similar efficacy compared with 
  
biological agents;109-113 moreover, in some countries csDMARD combination therapy 
is recommended by the national societies as preferred initial therapy.  
Other Task Force members pointed to trials that did not show a real benefit of 
combination therapy (especially when csDMARD monotherapy was combined with 
glucocorticoids in the comparator arms  );114-116 differences in glucocorticoid co-
intervention between combination- and monotherapy arms in previous trials;117 
issues concerning the design of some investigator initiated trials suggesting 
superiority of csDMARD combinations;118 the significantly higher rate of profound 
responses upon combination with bDMARDs compared with the combination with 
csDMARD therapy after insufficient response to MTX;112 and the higher level of 
toxicity of csDMARD combinations versus monotherapy.115;119 
It was also argued that a higher prevalence of adverse events when using 
combination therapy, even though often mild, may preclude escalation of therapy 
and result in not reaching a full dose of some of the drugs. Also, the SLR on 
csDMARDs did not show evidence for superiority of csDMARD combinations 
compared with csDMARD monotherapy.52 Moreover, the ACR Committee on the 
2015 update of the ACR management guideline, in contrast to previous versions,120 
did not longer recommend csDMARD combination as initial therapy, but prioritized 
MTX monotherapy.17 In line, the updated EULAR recommendations for the 
management of early arthritis do not advocate the use of csDMARD combination 
therapy.70 It was also pointed out that choice  ?Ă ?ŝŶĐůƵĚĞĚƚŚĞƚĞƌŵ “ƚƌĞĂƚŵĞŶƚ
ƐƚƌĂƚĞŐǇ ?ĂŶĚƚŚƵƐcomprised the option to use csDMARD combinations. These 
discussions resulted in a new ballot between two versions for recommendation 4: (a) 
 “DdyƐŚŽƵůĚďĞƉĂƌƚŽĨƚŚĞ ĨŝƌƐƚƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐǇ ? ?ĂƐĂďŽǀĞ ?; and (b)  “DdyƐŚŽƵůĚ
  
be the first csDMARD, either as monotherapy or in combination with other 
csDMARDs ?. In this 2nd ballot a 71% majority voted for version (a). Thus, csDMARD 
combination therapy is no longer presented explicitly as initial treatment suggestion 
within the abbreviated list of recommendations. It should be mentioned, though, 
that the simple fact that csDMARD combination therapy is not included in the bullet 
point anymore, does not preclude using it. This is obviously at the discretion of the 
physician and the patient in light of all pros and cons that had been discussed 
 ? ‘ƐŚĂƌĞĚĚĞĐŝƐŝŽŶ ? ?.  
This recommendation ultimately attained a very high level of agreement (9.8). The 
Task Force was well aware that in some countries, such as in the UK or Canada, 
rheumatologists are required to use at least two csDMARDs before the application of 
bDMARDs is approved by the payers and that combinations of two or three 
csDMARDs are accepted in lieu of two csDMARD courses. However, for the reasons 
just mentioned, the Task Force was not in favour of the practice to define an 
insufficient response to a combination of csDMARDs as a failure of two or more 
csDMARDs (when in reality it constitutes only one therapeutic strategy) nor to 
preclude the approval of bDMARD use when a first csDMARD has failed and the 
patient has bad prognostic markers (see below item 8 and Table 1). LoE 1a; LoA 9.8 
 
5. In patients with a contraindication to MTX (or early intolerance), leflunomide or 
sulfasalazine should be considered as part of the (first) treatment strategy. The 
contents of this recommendation were maintained; however, compared with the 
ƉƌĞǀŝŽƵƐǀĞƌƐŝŽŶŽĨŝƚĞŵ ? ?ƚŚĞǁŽƌĚŝŶŐ “ŝŶĐĂƐĞƐŽĨDdyĐŽŶƚƌĂŝŶĚŝĐĂƚŝŽŶƐ ?ǁĂƐ
slightly amended, because it is patients who have contraindications, rather than 
  
 ‘cases ?. The Task Force reiterated the relative safety of MTX and it was also discussed 
that the frequent fears of patients after reading the package insert should be 
addressed by providing appropriate information (overarching principle A). 
Nevertheless, there are occasional contraindications (e.g. kidney or liver disease) or 
intolerances. Under these circumstances, leflunomide (dosed at 20mg per day 
without loading dose)121 or sulfasalazine (escalated to 3g per day) are regarded the 
best alternatives. Older trials have suggested similar efficacy for both these drugs 
compared with MTX, although MTX was used at much lower doses than 
recommended today.122;123 However, no new trials have been performed to disprove 
the previous conclusions. Among all the above agents, only sulfasalazine has an 
acceptable safety profile during pregnancy.124 In some countries, parenteral gold is 
still utilized and, while clinical efficacy is undisputed, there are controversies 
regarding its safety;125;126 in other countries gold salts are not available any more. In 
contrast, the use of antimalarials, such as hydroxychloroquine and chloroquine, is 
still substantial, especially in combination therapy111 or as monotherapy in patients 
with very mild disease,127 particularly in China. Interestingly, antimalarials may have 
significant positive effects on lipid and glucose metabolism128 and may reduce 
cardiovascular risk in RA.129 However, joint damage is not retarded to a similar 
extent as with other csDMARDs.130 This recommendation also uses the term 
 “ƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐǇ ?ŝŵƉůǇŝŶŐ ?ĂƐǁŝƚŚDdy ?ƚŚĂƚůĞĨůƵŶŽŵŝĚĞĂŶĚƐƵůĨĂƐĂůĂǌŝŶĞĐĂŶ
be used as monotherapy or in combination with other csDMARDs or biologic 
agents.131-134 Indeed, step-up combination therapy is frequently employed, even 
though comparing step-up combination with switching of csDMARD did not reveal 
significant differences in outcomes.135 LoE 1a; LoA 9.0 
  
 
6. Short-term glucocorticoids should be considered when initiating or changing 
csDMARDs, in different dose regimens and routes of administration, but should be 
tapered as rapidly as clinically feasible. The added efficacy of glucocorticoids when 
combined with csDMARDs is well established. Indeed, hitherto all trials comparing 
glucocorticoids plus csDMARD with bDMARDs plus csDMARD revealed similar 
efficacy.135;136 In 2013, glucocorticoids were dealt with in recommendation 7, but the 
wording was different ? “Low-dose glucocorticoids should be considered as part of 
the initial treatment strategy (in combination with one or more csDMARDs) for up to 
6 months, but should be tapered as rapidly as clinically feasible ? ?The current 
wording constitutes a compromise attempting to accommodate most of the 
concerns and suggestions raised during thĞdĂƐŬ&ŽƌĐĞ ?Ɛ debate.  
TŚĞƚĞƌŵ “ůŽǁ-ĚŽƐĞ ? was critically discussed. While all members of the Task Force 
agreed that high doses of glucocorticoids should not be used for prolonged periods, 
ŝƚĂůƐŽďĞĐĂŵĞĐůĞĂƌƚŚĂƚƚŚĞůĂďĞů “ůŽǁ-ĚŽƐĞ ? (which means a daily dose of 7.5mg or 
less prednisone per day),137;138 while preferred by some Task Force members, does 
not capture several current ways of glucocorticoid application. Indeed, recent clinical 
trials have revealed the efficacy of short-term glucocorticoids, but at doses >7.5mg 
per day, namely orally at 30mg starting dose,115 as a single intramuscular injection of 
120mg methylprednisolone114 or as a single 250mg intravenous pulse therapy of 
methylprednisolone.136 Therefore, the term  “ůŽǁ-ĚŽƐĞ ?ǁĂƐĚĞůĞƚĞĚĂŶĚƌĞƉůĂĐĞĚďǇ
 “ƐŚŽƌƚ-ƚĞƌŵ ? ?ůĞĂǀŝŶŐƚŚĞchoice about  “ĚŽƐĞƌĞŐŝŵĞŶƐĂŶĚƌŽƵƚĞƐŽĨĂĚŵŝŶŝƐƚƌĂƚŝŽŶ ? 
(another new piece of wording in this item) to the individual rheumatologist and 
patient. Indeed, it was argued that a single intramuscular or intravenous application 
  
entails a much lower cumulative dose than a few weeks of oral low-dose therapy, 
but this view was not shared by all Task Force members.  
Yet another change involved the replacement of the phrase  “part of the initial 
treatment strategy ?ďǇ  “ǁŚĞŶŝŶŝƚŝĂƚŝŶŐŽƌĐŚĂŶŐŝŶŐĐƐDZƐ ? ?dŚŝƐĐŚĂŶŐĞ
clarifies the intention of the Task Force, in that glucocorticoids should be considered 
with all csDMARD starts, either as part of a first csDMARD therapy at the time of 
diagnosis or subsequently if an initial strategy has failed. Finally, the fact that 
csDMARDs are mentioned specifically implies that glucocorticoids are typically not 
needed as a bridging therapy when bDMARDs or tsDMARDs are used, as these 
usually have a rapid onset of action and the infection risks may be potentiated139;140 
Thus, it is important to reiterate that the Task Force recommends using 
glucocorticoids in combination with csDMARDs primarily as bridging therapy until 
the csDMARD reaches its maximum effect, and this should be done using one of the 
dosing and tapering approaches mentioned above, for which respective evidence 
exists. To reflect the position of the Task Force, the algorithm depicted in Figure 1 
ǁĂƐŵŽĚŝĨŝĞĚƚŽƐŚŽǁĂ “A? ?ĨŽƌƚŚĞƵƐĞŽĨŐůƵĐŽĐŽƌƚŝĐŽ ĚƐŝŶƚŚĞŶĞǁǀĞƌƐŝŽŶƌĂƚŚĞƌ
ƚŚĂŶĂ “A? ?ĂƐƉƌĞǀŝŽƵƐůǇ ? 
 
By stating  “ ?ƚapered as rapidly as clinically feasible ?the Task Force underlines that 
glucocorticoids should be gradually reduced and ultimately stopped, usually within 3 
months from treatment start and only exceptionally by 6 months. Long-term use of 
glucocorticoids, especially at doses above 5mg per day, should be avoided because 
of the many potential risks presented in the SLR.50;52;57 While some of these risk 
associations may be due to confounding by indication in patients with high disease 
  
activity,141 the evidence for increased overall and cardiovascular mortality at a dose 
above a threshold of 7.5mg/day or a cumulative dose of 40g is considerable.142 Of 
note, applying glucocorticoids as a sole therapeutic change in patients with 
insufficient response to csDMARD therapy does not convey good efficacy and is 
associated with significant adverse events.143 Moreover, if glucocorticoids cannot be 
withdrawn within the time frame mentioned above, the DMARD therapy may have 
to be considered a failure. Finally, intra-articular glucocorticoid application may have 
to be considered in certain instances, such as a residually inflamed or a reactivated 
joint. 
Some Task Force members advocated the chronic use of glucocorticoids as a 
possibility for some patients, however, this proposal was not endorsed by the 
majority. While the bullet point on glucocorticoids was, as in previous years, most 
heavily debated, the final wording received a 98% majority vote. The level of 
agreement, though, was much lower (8.7), in line with previous versions of the 
recommendations. This relatively low level of agreement is presumably due to the 
fact that many task force members felt that this point was too liberal and the use of 
glucocorticoids should be more restricted, while others were of the opinion that it 
was too restrictive. LoE 1a; LoA 8.7 
 
7. If the treatment target is not achieved with the first csDMARD strategy, in the 
absence of poor prognostic factors, other csDMARDs should be considered. This 
sentence constitutes the first part of previous recommendation 8. It is essentially 
ǁŽƌĚĞĚŝŶĂŶŝĚĞŶƚŝĐĂůǁĂǇ ?ĞǆĐĞƉƚƚŚĂƚƚŚĞůĂƐƚƉŽƌƚŝŽŶ ? “ĐŚĂŶŐĞƚŽĂŶŽƚŚĞƌ
ĐƐDZƐƚƌĂƚĞŐǇƐŚŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚ ? ?ǁĂƐƌĞǁŽƌĚĞĚĂƐ “ŽƚŚĞƌĐƐDZƐ
  
ƐŚŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚ ?, in light of the fact that combination with glucocorticoids has 
now been recommended clearly also for this step of the treatment algorithm (item 
6) and combinations of csDMARDs are not specifically recommended as initial 
treatment strategy anymore. The poor prognostic factors are presented in Table 1. 
The Task Force also discussed that early intolerance for a csDMARD should not be 
considered as a treatment failure, which would imply moving immediately to the 
next phase of the algorithm, but rather require re-institution of another first 
csDMARD (replacement). LoE 5; LoA 8.5 
 
8. If the treatment target is not achieved with the first csDMARD strategy, when poor 
prognostic factors are present, addition of a bDMARD* or a tsDMARD* should be 
considered; current practice would be to start a bDMARD§. The separation of the 2nd 
ƉĂƌƚŽĨƉƌĞǀŝŽƵƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶ ? ? “when poor prognostic factors are present, 
ĂĚĚŝƚŝŽŶŽĨĂďDZƐŚŽƵůĚďĞĐŽŶƐŝĚĞƌĞĚ ? ?and the new item 7 reflects the Task 
&ŽƌĐĞ ?ƐĚĞƐŝƌĞƚŽgive stratification by prognostic factors more prominence. The 
bDMARDs currently available include a series of TNF-inhibitors (adalimumab, 
certolizumab, etanercept, golimumab and infliximab); abatacept (a costimulation 
inhibitor); tocilizumab (an IL-6 receptor blocker, but in the future also possibly 
another IL-6 receptor inhibitor, sarilumab, and IL-6 inhibitors, such as clazakizumab 
or sirukumab); rituximab (an anti-B-cell agent); both as biological originator (bo) 
DMARDs and as EMA- or FDA- approved biosimilar (bs) DMARDs.  
 
This recommendation was also expanded to include tsDMARDs, namely the Jak 
inhibitor tofacitinib and possibly further Jak inhibitors, such as baricitinib. In the 
  
2013 update, tsDMARDs (bullet point 11) were recommended for use after a 
bDMARD had failed. Since then, more data on tofacitinib, especially regarding long-
term safety aspects, and new data for baricitinib have been published. The data 
suggest that baricitinib may be more efficacious than a TNF-inhibitor.144 Currently, 
the term tsDMARDs refers only to Janus kinase (Jak) inhibition. Tofacitinib is 
approved in many countries, such as in the USA, Latin America and Asia as well as 
some European countries, but still not in the European Union; baricitinib has 
completed phase 3 trials and is currently under regulatory review; and filgotinib and 
other Jak inhibitors are undergoing evaluation in clinical trials. However, similar to 
the 2010 recommendations, in which TNF-inhibitors had been given a slight 
preference over other biologics due to availability of long-term registry data for the 
former but not the latter, preference is given here to bDMARDs over Jak inhibitors 
for the same reason. This notion on current practice is an expert opinion and not 
based on solid evidence. This bullet point still received a very high vote at the 
meeting and a high level of agreement.  
The recommendation to use these agents in patients who have bad prognostic 
factors (rather than those who have not) is also not based on solid evidence in the 
literature. However, in most trials of bDMARDs and tsDMARDs the existing inclusion 
criteria, such as high disease activity, presence of autoantibodies and pre-existing 
joint damage, assured that patients with bad prognostic factors were included. 
Nevertheless, formal trials comparing the use of any of these agents in patients with 
and without bad prognostic markers do not exist. On the other hand, several post-
hoc analyses revealed the value of using TNF-inhibitors in patients with bad 
prognostic markers (Table 1) relative to those without.69;145  
  
 
The footnote to bDMARDs mentions that all approved bDMARDs may be used 
without hierarchical positioning, and that EMA- or FDA-approved biosimilars 
(bsDMARDs) have similar efficacy and safety as the respective biological originator 
(bo) DMARDs,  and should be preferred if they are indeed appreciably cheaper than 
originator or other bDMARDs or tsDMARDs. Since the 2013 update, several 
bsDMARDs targeting TNF have been approved in Europe and some in the USA.146-148 
Among the bDMARDs there is no difference in outcomes, irrespective of their target. 
This conclusion rests on head-to-head trials,  meta-analyses, the results of the SLRs, 
50-52;149  and indirect comparison (the latter being less reliable and therefore least 
informative)13;150;151 Of note, the SLR also included data from clinical trials of 
sarilumab, a human anti-IL-6 receptor antibody, and sirukumab, a human anti-IL-6 
antibody, both of which are not approved at the present time; based on the SLR, the 
Task Force regarded these two antibodies and tocilizumab as having overall similar 
efficacy and safety51.  
While rituximab is approved for use after TNF-inhibitors have failed, there is ample 
evidence for its efficacy in bDMARD-naïve patients and early RA.60;150 It is, therefore, 
frequently used after insufficient response to csDMARDs, especially when there are 
specific contraindications to other biologic agents, such as past lymphoma or 
demyelinating disorders, given its efficacy in these diseases.152;153  
The separation of points 7 and 8 was also based on the reason that the previous 
bullet point comprised of two recommendations and that separating them would 
give the stratification by prognostic factors better visibility. The poor prognostic 
factors are presented in Table 1 and now also include failure of two csDMARDs; if 
  
patients have insufficient efficacy to two csDMARD courses, either consecutively or 
as combination, a further csDMARD may have only little additional impact.116;154  
The Task Force also discussed whether the use of a bDMARD as first-line therapy 
should be reconsidered, as had been the case in the original 2010 recommendations. 
Such use has been tested in a large number of randomized trials and has consistently 
been found to be statistically superior to MTX monotherapy. Importantly, however, 
none of the respective phase 3 trials used a combination with de novo 
glucocorticoids in the MTX monotherapy arm and the few investigator-initiated 
studies that compared first-line bDMARDs plus MTX with glucocorticoids plus MTX 
(or with a combination of csDMARDs) did not show a clear clinical or structural 
advantage of early bDMARD therapy.116;136 Also, embedded within responders to 
initial treatment with bDMARDs+MTX are 20-25% good responders to MTX alone, 
leading to overtreatment of these patients.155 Finally, it was shown that patients 
who had an insufficient response to MTX but then rapidly received bDMARD 
responded to a similar extent as those who had started with the bDMARD plus 
MTX.68 Thus, this proposal did not find a majority vote.  
Nevertheless, it is still conceivable that an induction regimen followed by the 
subsequent cessation of the bDMARD and continuation of the csDMARD may 
become a valuable option in the future; there is some support in the literature for 
such an approach.68;156-159 However, this would need further confirmation by 
additional trials before it could be put into place, especially also because the number 
of initial responders in whom tapering could be considered does not comprise a 
majority of the patients. The recommendation, as worded above, received 94% of 
ƚŚĞdĂƐŬ&ŽƌĐĞŵĞŵďĞƌƐ ?ǀŽƚĞƐ. LoE *1b, §5; LoA 9.0 
  
 
9. bDMARDs* and tsDMARDs# should be combined with a csDMARD; in patients who 
cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs may 
have some advantages compared to other bDMARDs. This recommendation replaces 
former no.  ? ? “/ŶƉĂƚŝĞŶƚƐƌĞƐƉŽŶĚŝŶŐŝŶƐƵĨĨŝĐŝĞŶƚůǇƚŽDdyĂŶĚ ?ŽƌŽƚŚĞƌĐƐDZ
strategies, with or without glucocorticoids, bDMARDs [TNF inhibitors, abatacept or 
tocilizumab, and, under certain circumstances, rituximab] should be commenced 
ǁŝƚŚDdy ? ?. While the individual bDMARDs and tsDMARDs have been already 
discussed above, item 9 now refers to the fact that all bDMARDs have superior 
efficacy when combined with MTX than as monotherapy. Compared with the 2013 
update, more evidence has now accrued in favor of combination, even for 
tocilizumab.160-162 Also for baricitinib, combination therapy conveys better structural, 
though not clinical or functional efficacy than monotherapy.163 However, regarding 
signs and symptoms, physical function and joint damage, there are indications for a 
somewhat better efficacy of tocilizumab monotherapy, and more strongly so for Jak-
inhibitors compared with MTX.163-165 Monotherapy of the other biologic agents has 
not been found clinically superior to methotrexate monotherapy.66;67;166 MTX can be 
used at 7.5 to 10mg to provide added efficacy to TNF-inhibitors167;168 and intolerance 
at these low doses leading to discontinuation is very rare. Moreover, biologics can 
also be effectively combined with other csDMARDs.131;133  
Another aspect, namely the occurrence of anti-drug antibodies (immunogenicity), 
was discussed, especially regarding secondary non-response. In this context the lack 
of knowledge about the role of non-adherence and non-persistence was also 
addressed.  The Task Force then discussed routine testing of anti-drug-antibodies 
  
and drug levels and felt that there was little place for these in clinical practice, since 
a good clinical response would not lead to cessation of therapy even in the presence 
of anti-drug antibodies, or low drug levels, and vice versa. Of note, the use of MTX at 
the doses mentioned above reduces the incidence of anti-drug antibodies.167;168  
For all these reasons the Task Force felt strongly (96% majority) that bDMARDs (and 
tsDMARDs) should primarily be added to, i.e. combined with csDMARDs, such as 
MTX or leflunomide, leaving the option of monotherapy,  with a preference for 
certain drugs, as an exception in case of intolerance or contraindication to all 
csDMARDs. LoE *1a, #1b; LOA 9.2 
 
10. If a bDMARD* or tsDMARD§ has failed, treatment with another bDMARD or a 
tsDMARD should be considered; if one TNF inhibitor therapy has failed, patients may 
receive another TNF inhibitor or an agent with another mode of action. A similar 
recommendation was presented ŝŶ ? ? ? ? ? “/ĨĂĨŝƌƐƚďDZ has failed, patients 
should be treated with another bDMARD; if a first TNF inhibitor therapy has failed, 
patients may receive another TNF inhibitor or a biological agent with another mode 
of action ? ?Indeed, in a trial published after the elaboration of these 
recommendations, even primary non-responders to a TNF-inhibitor were shown to 
have some response to another anti-TNF, making ti difficult to draw different 
conclusions for subsequent therapy for primary compared with secondary failures to 
TNF-blockers.169 The addition ŝŶƚŚĞĨŝƌƐƚƉĂƌƚ ? “ŽƌƚƐDZ ? ?ǁĂƐƉĂƌƚůǇŶĞĞĚĞĚ
because tsDMARDs (Jak inhibition) are now included in the earlier recommendations 
8 and 9 ? “ĨŝƌƐƚ ?ǁĂƐĚĞůĞƚĞĚ ?ďĞĐĂƵƐĞthe Task Force did not decide to distinguish 
between failure of one or more bDMARDs. However, it must be noted that it is 
  
currently neither known if a Jak inhibitor is effective once another one has failed nor 
established that a second IL-6 receptor inhibitor or inhibitors of the IL-6 ligand are 
effective if tocilizumab has failed  ? this is still part of the research agenda. We also 
lack studies exploring if TNF-inhibitors are efficacious and safe after bDMARDs with 
other modes of action have failed, and also studies investigating switching between 
these other modes of action. A few members raised the question if the use of 
csDMARDs should also be considered when bDMARDs had failed, but this suggestion 
did not find a majority.  
The Task Force was also clear about its recommendations that any bDMARD, 
including another TNF-inhibitor, could be used if a TNF-inhibitor has previously 
failed. Thus, drugs with the same or with another mode of action are recommended 
in this situation. This was based on the data of clinical trials including meta-
analyses149 and on the fact that in contrast to registry data, which may be affected 
by a variety of confounders, several new prospective studies suggest that there is no 
difference between these two approaches.170;171 If a second TNFi fails, patients 
should receive an agent with another mode of action. However, it is self-evident 
(and supported by the vast majority of the Task Force members) that a bsDMARD of 
any of the reference boDMARDs should not be used if the respective boDMARD (or 
another bsDMARD of the same molecule) has failed to induce sufficient efficacy or 
vice versa. LoE *1a, §5; LoA 9.2 
 
11. If a patient is in persistent remission after having tapered glucocorticoids, one can 
consider tapering bDMARDs, especially if this treatment is combined with a 
csDMARD. This item remained unchanged compared to the 2013 publication. No 
  
new data have been published that contest this conclusion. Tapering here means 
reduction of dose or extension of interval between applications  ? ‘ƐƉĂĐŝŶŐ ? ?. It does 
not necessarily imply discontinuation of a bDMARD, which may lead to a recurrence 
of disease in a majority of patients.172;173 However, even if treatment is stopped and 
patients flare, the majority of them (>80%) will recover their previous good outcome 
upon reinstitution of therapy (but some do not),173;174 and patients should be 
informed accordingly. There exist certain predictors in whom tapering will be likely 
successful and these relate primarily to early RA, depth of improvement and 
duration of remission;175 prospective trials taking these aspects into consideration 
are needed in the future. This item also indirectly bolsters recommendation no. 9 on 
combination therapy of bDMARDs with MTX or another csDMARD, since it implies 
that bDMARDs should primarily, if not only, be tapered and possibly discontinued 
when combined with a csDMARD, while tapering and stopping of bDMARD 
monotherapy was not yet sufficiently studied. LoE 2b; LoA 9.0 
 
12. If a patient is in persistent remission, tapering the csDMARD could be considered. The 
2013 version of the respective point 13 reads:  “/ŶĐĂƐĞƐŽĨƐƵƐƚĂŝŶĞĚůŽŶŐ-term 
remission, cautious reduction of the csDMARD dose could be considered, as a shared 
decision between patient and physician ?. This item elicited significant discussions, 
since it would mean leaving patients with RA either without any or with a low dose 
of a csDMARD. But in general, no new evidence for or against this view has been 
found over the last years. In the discussion, controversies emerged. It was 
mentioned that here tapering means primarily reducing the dose and that 
discontinuing csDMARDs may be possible only in exceptional cases. Many 
  
rheumatologists on the Task Force panel, though, expressed a view stating that 
csDMARDs should never be stopped. Consequently, this item received the lowest 
level of agreement (8.5) of all, although still quite high on the scale of 0 to 10. Of 
note, the portion worded  “ĂƐĂƐŚĂƌĞĚĚĞĐŝƐŝŽŶďĞƚǁĞĞŶƉĂƚŝĞŶƚĂŶĚƉŚǇƐŝĐŝĂŶ ?ǁĂƐ
now deleted. It was felt by the Task Force that mentioning the shared decision for 
this item among all 12 would imply that the other recommendations may not need 
to involve the patient, or single out this specific recommendation in comparison with 
all other ones and thus offset overarching principle A. Obviously, the removal of this 
phrase does not mean that shared decision making with the patients is not 
important, on the contrary: in line with principle A it is of utmost importance for this 
and for all other recommendations. LoE 4; LoA 8.5 
 
 
The updated recommendations are depicted in an abbreviated way in Figure 1. Part and 
parcel of this figure are the respective footnotes as well as the full text as presented here. 
 
 
 
 
 
DISCUSSION 
 
The 2016 update of the EULAR RA management recommendations was developed by 50 
experts, including patients, rheumatologists and other health care professionals. This was 
  
the largest Task Force ever convened for the development of EULAR recommendations, 
both with respect to the overall number of members and the number of European countries 
involved, and it is also the first EULAR Task Force with a broad international representation, 
since rheumatologists from several other continents participated in this activity. This 
allowed us to also include some views from Asia, and Latin- and North America in the 
development of the recommendations, an input desired given the information provided in 
the recent publications of the updated ACR and the APLAR recommendations.17;39 
dŚĞ ? ? ? ?ƵƉĚĂƚĞƉƌĞƐĞŶƚƐƚŚĞŚŝƚŚĞƌƚŽ “ůĞĂŶĞƐƚ ?h>ZƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĨŽƌZ
management. While in 2010 the document comprised of 3 overarching principles and 15 
recommendations and in 2013 it contained 3 overarching principles and 14 
recommendations, the 2016 update arrived with 4 principles and 12 recommendations. 
Despite this reduction, in light of a continuously increasing spectrum of therapeutic options 
and new information on existing agents and therapeutic strategies, this update covers more 
treatment aspects and is built on a better evidence base than ever before. This is due to the 
availability of at least partial answers to several of the research questions posed in 2013, 
such as items 4, 6, 9 and 21,16 and of many new data on established and novel drugs as well 
as therapeutic strategies. 
The Task Force adhered to several principles established in the course of the development 
of the 2013 update and even in 2010. For example, aside from evidence on efficacy and 
safety, economic aspects were generally considered in line with respective general 
specifications.45;46 Also, agents that have not yet been approved by regulatory authorities 
but for which data from phase III trials were available, were considered with the caveat that 
their use would be only possible upon such approval. This pertains to bsDMARDs, for which 
  
the Task Force relies on the stringency of the regulatory processes of EMA and FDA, for new 
IL-6 inhibitors and for Jak inhibitors, the first of which is currently only licensed in some 
parts of the world with increasing availability of data on others. Finally, the Task Force 
reiterated its previous conclusions on the importance of stratification according to risk 
factors of adverse RA outcome, 69;145 once an initial therapy has failed. 
The individual recommendations are not numbered by importance, but rather by a logical 
sequence: what is the treatment target and how should the patient be followed? What is 
the most prudent treatment approach once the diagnosis has been made? How can 
therapeutic success be maximized? Which therapies should follow a first treatment failure 
(phase I) and under which circumstances? Which agent or type of drug should be preferred 
in the course of the development of the treatment strategies?   
Consequently, the first three items, which were either left fully unchanged or were only 
minimally changed, deal with the time point of starting effective therapy (as soon as the 
diagnosis is made and thus without any loss of time); with the definition of the treatment 
target (sustained remission or low disease activity); and with monitoring and the need to 
reach a significant improvement of disease activity within 3 months and attainment of the 
targeted state within 6 months. The preferred instruments to be used when following 
patients have been defined in previous EULAR activities22;100 and comprise composite 
measures that include joint counts, such as the DAS28, CDAI and SDAI as well as the 
ACR/EULAR remission definitions. Of note, instruments weighing acute phase reactants 
highly, may exaggerate response, especially with IL-6 or Jak inhibitors.  
The treatment target (stringent remission or low disease activity) continues to be clinically 
defined, since focusing at ultrasonographic remission has not shown better outcomes 
  
compared with targeting clinical low disease activity or stringent remission, but rather 
induced overtreatment and thus inefficient use of healthcare resources.97;98 Moreover, no 
strategy trial is available comparing the use of the serologic multi-biomarker disease activity 
(MBDA) test with targeting remission using clinical disease activity assessment by a clinical 
composite measure (with which MBDA correlates anyway); of note, the MBDA test has been 
reported to improve to a larger extent upon using a bDMARD that directly targets a cytokine 
compared with one that targets T-cell co-stimulation, despite similar clinical, functional and 
radiographic outcomes.176 Moreover, it must be assumed that such test would falsely 
indicate high disease activity when an infection occurs. For all these reasons, the Task Force 
recommends to follow patients in clinical practice using a composite measure which 
comprises joint counts and may include an acute phase reactant. This clinical assessment is 
pertinent for every therapeutic phase (Figure 1).  
Subsequent recommendations, however, have undergone some significant changes 
compared with the 2013 update. While MTX (or in the presence of intolerance another 
csDMARD) continues to be considered the pivotal drug once the RA diagnosis has been 
made (item 4), it is recommended more strongly than before to escalate MTX to a dose of 
25-30mg weekly (with folate supplementation), given further recent insights on the high 
response rate with such strategy. 4;107 Moreover, the combination of csDMARDs, as 
monotherapy, with glucocorticoids (GC) is more strongly suggested than before in light of 
increasing evidence that this combination is not surpassed by csDMARD combinations, even 
if they are applied with glucocorticoids, or bDMARDs plus MTX in terms of efficacy and 
safety.115;136 In the treatment algorithm (Figure 1, phase I), this is reflected by the respective 
change from  “± ? to  “+ ?ĨŽƌƚŚĞĂĚĚŝƚŝŽŶŽĨŐůƵĐŽĐŽƌƚŝĐŽŝĚs to csDMARDs. dŚĞƚĞƌŵ “ůŽǁ
ĚŽƐĞ ?'ŚĂƐŶŽǁďĞĞŶƌĞƉůĂĐĞĚďǇ “ƐŚŽƌƚ- Ğƌŵ ?' ?ŐŝǀĞŶƚŚĂƚǀĂƌŝŽƵƐŵŽĚĞƐŽĨ
  
application at different doses have shown to be efficacious. Moreover, the most important 
factors to reduce the risk of adverse event, such as cardiovascular events, infections, 
diabetes, or hypertension,141;142;177 was deemed to be rapid tapering to discontinuation and 
a low cumulative dose of GC. This is, indeed, the case with these alternative glucocorticoid 
treatment modalities.   
In contrast to the 2013 update, csDMARD combination therapy, with or without 
glucocorticoids, is no longer an explicit part of the recommendations. This conclusion was 
based on the accruing evidence that this csDMARD combination therapy may not be superior 
to MTX monotherapy plus GC, but may be associated with an increase in adverse events.115;119 
A recent indirect-comparison meta-analysis has suggested a superiority of csDMARD 
combination vs MTX monotherapy.178 Not only was this study at odds with a previous direct-
comparison meta-analysis35;179 and with our own SLRs,35;35;52;180 but indirect comparisons 
should also be considered with reservation since their rigor and value is insufficiently 
understood to date. Interestingly, using a somewhat different approach and based on an 
independent SLR, the ACR guideline has arrived at a similar conclusion as presented here and 
recommends MTX monotherapy as the first DMARD in early or established RA.17 However, 
the use of csDMARD combination therapy is not precluded by the new recommendations, 
rather it is at the discretion of the rheumatologist to apply it in the context of the 
recommendation on the use of MTX as a (first) ƚƌĞĂƚŵĞŶƚ “ƐƚƌĂƚĞŐǇ ? ?  
Once phase I has failed to reach the treatment target, either in the presence of bad 
prognostic markers or in the absence of bad prognostic markers after a second csDMARD 
strategy has failed, the Task Force recommends to add any bDMARD or, less preferably, a 
tsDMARD. If phase II as depicted in the algorithm fails to arrive at the treatment target, 
  
another bDMARD or a tsDMARD should be used. The Task Force reiterated its position that 
if a TNF inhibitor fails, another TNF inhibitor  ? but not a biosimilar of the same molecule!  ?  
can be as effective as changing the mode of action. Vice versa, an effective biologic agent 
should not be switched to a biosimilar of another bDMARD for non-medical reasons. 
However, important data are missing for some of the drugs; for example, clinical trials did 
not address the efficacy of a TNF-inhibitor after bDMARDs with other modes of action or a 
Jak inhibitor have failed. Similar questions arise for the other agents and also for the use of 
IL-6 inhibitors, such as sarilumab or sirukumab, after tocilizumab has failed (see also 
research agenda). 
Early bDMARD treatment, including an induction regimen with subsequent withdrawal of 
bDMARDs as supported by some strategy trials, was discussed but did not find a majority 
among the Task Force members. This decision was based on the lack of evidence for 
superiority of such therapy compared with the use of MTX plus glucocorticoids. Moreover, 
when placed in the context of a treat-to-target strategy, the initial use of csDMARDs yields 
equal results in the long-term. Finally the cost-effectiveness of first-line bDMARD therapy, 
especially in light of the reasons just mentioned, is very poor.  
The 2016 update of the EULAR recommendations is based on the most recent evidence in 
the area of RA management and on discussions by a large and broadly international Task 
Force. The recommendations synthesize the current thinking on approaching RA treatment 
in a set of overarching principles and recommendations. These have been informed by SLRs 
on the efficacy and safety of the drugs. The Task Force is convinced that adhering to these 
recommendations, including shared decision making, defining the treatment target, 
assessing disease activity regularly with appropriate instruments and applying the sequence 
  
of drugs as proposed and in a treat-to-target strategy, will maximize the overall outcome in 
a vast majority of RA patients. Still, a considerable proportion of patients will not reach the 
target despite all efforts, and for these patients new drugs will be needed. Also, new 
information from research activities on treatment strategies, predictive markers, and other 
aspects will become available in the near future and will likely necessitate yet another 
update of the recommendations in about 3 years; maybe we will then have new data on the 
research agenda, including precision medicine approaches in RA which allow predicting who 
will best respond to which drug at which stage of the disease. Until then we hope that the 
2016 update will be broadly applied in clinical practice and/or serve as a template for 
national societies to develop local recommendations. 
 
Acknowledgement. The Task Force gratefully acknowledges the financial support by EULAR. 
Participation in EULAR Task Forces requires a priori declaration of conflicts of interest which 
has been done by all Task Force members. One Task Force member, who had attended the 
face-to-face meeting and had participated in all voting processes thereof decided to 
withdraw from the Task Force subsequently because some of that persŽŶ ?ƐǀŝĞǁƐŚĂĚŶŽƚ
found a majority during the voting process. This withdrawal occurred without casting a vote 
for the level of agreement with the recommendations. We thank this member for the 
contributions to the discussion process. 
 
  
  
Table 1. Glossary and definitions 
TERM DEFINITION 
Poor prognostic factors x Moderate (after csDMARD therapy) to 
high disease activity according to 
composite measures181 
x High acute phase reactant levels182;183 
x High swollen joint counts182-184 
x Presence of RF and/or ACPA, especially 
at high levels182;185 
x Combinations of the above69;145 
x Presence of early erosions182 
x Failure of 2 or more csDMARDs154 
Low dose glucocorticoid x <7.5mg/day (prednisone 
equivalent)57;137 
Meanings of treatment reduction x  
Tapering x Usually reduction of drug dose or 
increase of application interval 
 ? ‘ƐƉĂĐŝŶŐ ? ? 
x May include discontinuation (tapering 
to 0), but then only after slow reduction 
Cessation, discontinuation Stopping of a particular drug 
Disease activity states 
Remission ACR-EULAR Boolean or index-based remission 
definition22 
Low disease activity Low disease activity state according to any of 
the validated composite disease activity 
measures that include joint counts186-188 
Moderate, high disease activity Respective disease activity state according to 
any of the validated composite disease activity 
measures that include joint counts186-188 
DMARD nomenclature12 
Synthetic DMARDs (sDMARDs) x Conventional 
synthetic 
DMARDs 
(csDMARDs) 
E.g. methotrexate, 
leflunomide, 
sulfasalazine, 
hydroxychloroquine 
x Targeted 
synthetic 
DMARDs 
(tsDMARDs) 
E.g. tofacitinib 
Biological DMARDs (bDMARDs) x Biological originator DMARDs 
(boDMARDs) 
x Biosimilar DMARDs (bsDMARDs) 
 
  
  
Table 2. The 2016 EULAR Updated Recommendations 
 Overarching Principles 
A Treatment of RA patients should aim at the best care and must be based on a shared decision 
between the patient and the rheumatologist. 
B Treatment decisions are based on disease activity and other patient factors, such as progression 
of structural damage, comorbidities and safety issues. 
C Rheumatologists are the specialists who should primarily care for RA patients. 
D RA incurs high individual, medical and societal costs, all of which should be considered in its 
management by the treating rheumatologist. 
  
 Recommendations 
  1. Therapy with DMARDs should be started as soon as the diagnosis of RA is made. 
  2. Treatment should be aimed at reaching a target of sustained remission or low disease activity in 
every patient. 
  3. Monitoring should be frequent in active disease (every 1 ?3 months); if there is no improvement 
by at most 3 months after the start of treatment or the target has not been reached by 6 
months, therapy should be adjusted. 
  4. MTX should be part of the first treatment strategy. 
  5. In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine 
should be considered as part of the (first) treatment strategy. 
  6. Short-term glucocorticoids should be considered when initiating or changing csDMARDs, in 
different dose regimens and routes of administration, but should be tapered as rapidly as 
clinically feasible. 
  7. If the treatment target is not achieved with the first csDMARD strategy, in the absence of poor 
prognostic factors, other csDMARDs should be considered. 
  8. If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic 
factors are present, addition of a bDMARD*1,2 or a tsDMARD*3 should be considered; current 
practice would be to start a bDMARD§. 
  9. bDMARDs*1,2 and tsDMARDs#3 should be combined with a csDMARD; in patients who cannot use 
csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs may have some advantages 
compared to other bDMARDs. 
10. If a bDMARD* or tsDMARD§ has failed, treatment with another bDMARD or a tsDMARD should 
be considered; if one TNF inhibitor therapy has failed, patients may receive another TNF 
inhibitor or an agent with another mode of action. 
11. If a patient is in persistent remission after having tapered glucocorticoids, one can consider 
tapering bDMARDs, especially if this treatment is combined with a csDMARD. 
12. If a patient is in persistent remission, tapering the csDMARD could be considered. 
DMARDs, disease modifying antirheumatic drugs; boDMARDs, biological originator 
DMARDs; bsDMARD, biosimilar DMARDs; csDMARDs, conventional synthetic DMARDs; 
tsDMARDs, targeted synthetic DMARDs 
1TNF-inhibitors: adalimumab, certolizumab pegol, etanercept, golimumb, infliximab 
boDMARDs or the respective EMA/FDA approved biosimilars; 2abatacept, rituximab (as first 
bDMARD under special circumstances  ? see text), or tocilizumab or respective FDA/EMA 
approved biosimilars, as well as other IL-6 pathway inhibitors, sarilumab and/or sirukumab, 
once approved. 3Jak-inhibitors (where approved) 
  
*,§,#These symbols indicate different levels of evidence which are correspondingly provided 
together with voting results and levels of agreement in Table3.  
  
Table 3. Evidence levels, voting results and agreement 
  
 LoE SoR Final vote (%) Level of Agree-
ment (0-10) 
A n.a. n.a. 100 9.9 
B n.a. n.a. 100 9.9 
C n.a. n.a. 100 9.8 
D n.a. n.a.   98 9.7 
     
  1. 1a A   96 9.9 
  2. 1a A   91 9.6 
  3. 2b  100 9.5 
  4. 1a A   71 9.8 
  5. 1a A   85 9.0 
  6. 1a A   98 8.7 
  7. 5 D   94 8.5 
  8. *1b 
§5 
*A 
§D 
  96 9.0 
 
  9. *1a 
#1b   
*A 
#A 
  96 9.2 
10. *1a 
§5 
A* 
§D 
  71 9.1 
11. 2b B   86 9.0 
12. 4 C   86 8.5 
 
*,§,#These symbols relate to the corresponding symbols in the recommendations (Table 2), 
showing the respective levels of evidence. 
 
BOX: Research Agenda 
1. How does MTX monotherapy in combination with glucocorticoids compare to 
monotherapies of sulfasalazine or leflunomide in combination with glucocorticoids, 
at the doses of csDMARDs as used today? 
2. In what proportion of  patients is an induction therapy with a bDMARD+MTX with 
subsequent cessation of the bDMARD effective in inducing sustained remission?  
3. Is the application of a TNF-inhibitor after abatacept, tocilizumab, rituximab or a Jak 
inhibitor has failed, safe and efficacious? 
4. How safe and efficacious are abatacept, tocilizumab and rituximab after any of the 
other non-TNFi-bDMARDs or a tsDMARD has failed? H 
5. How safe and efficacious is the use of an IL-6 pathway inhibitor if another another IL-
6 pathway inhibitor/another Jak-inhibitor has failed? 
6. How safe and efficacious is the use of a Jak-inhibitor after another another IL-6 
pathway inhibitor/another Jak-inhibitor has failed? 
  
7. Is the risk stratification as recommended by EULAR after failure of MTX improving 
outcome in those with risk factors and not harming those without bad prognostic 
markers? Do patients who lack bad prognostic factors benefit as much from a switch 
or addition of a csDMARD as from the addition of a bDMARD? 
8. Can we find predictors of differential response to the different bDMARDs and 
tsDMARDs? 
9. When starting a DMARD, how can we best predict who will attain the treatment 
target (remission or low disease activity) and who not? 
10. Can we predict who will maintain remission after withdrawal a bDMARD? 
11. Will we be able to develop precision (personalized, stratified) medicine approaches 
in RA? 
12. Is tapering of bDMARD monotherapy, where potentially indicated, comparable with 
bDMARD tapering in the presence of csDMARDs? 
13. Will RCTs on tapering of bDMARDs following the deducted predictors for successful 
withdrawal of bDMARDs show success? 
14. How good is patient adherence to a bDMARD or tsDMARD and can non-adherence 
explain secondary loss of efficacy? 
15. Is measurement of serum drug or anti-drug antibody levels useful in clinical practice? 
16. Which biomarkers will help to find better predictors of bad outcome or response and 
which have failed in the numerous clinical trials that evaluated gene-expression and 
other biomarkers? 
17. What is the effect of csDMARD, tsDMARD and bDMARD therapies on cardiovascular 
outcomes and to which extent is a potential effect dependent on a clinical response? 
18. Is the use of telemedicine or e-medicine approaches as effective as direct contact in 
the clinic for treat-to-target strategies? 
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